Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F

Rhea-AI Summary

Ambrx Biopharma Inc. (NYSE: AMAM) has filed its annual report on Form 20-F with the SEC for the year ended December 31, 2021. The report, which includes audited consolidated financial statements, is available on both the SEC and company websites. Ambrx utilizes an expanded genetic code technology platform to develop Engineered Precision Biologics, focusing on antibody drug conjugates and immuno-oncology therapies. The company offers a free hard copy of the annual report upon request to shareholders.

Positive

• Filed annual report on Form 20-F, providing transparency for investors.
• Utilizes a unique genetic code technology platform to create innovative biopharmaceuticals.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that it filed its annual report on Form 20-F (the “Form 20-F”) for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on April 26, 2022. The Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Company’s website at www.ambrx.com.

The Company will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and holders of its American Depositary Shares upon request. Requests should be directed in writing by email to ir@ambrx.com.

About Ambrx Biopharma Inc. (Ambrx)

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005647/en/

Ambrx Biopharma Inc.

INVESTORS

Laurence Watts, Managing Director

Gilmartin Group, LLC.

619-916-7620

ir@ambrx.com

MEDIA

media@ambrx.com

Source: Ambrx Biopharma Inc.

FAQ

What did Ambrx Biopharma announce in April 2022?

Ambrx announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2021.

Where can I access Ambrx's Form 20-F?

The Form 20-F can be accessed on the SEC's website or Ambrx's official website.

What is the significance of Ambrx's Form 20-F filing?

The Form 20-F filing provides detailed financial and operational data, offering transparency to investors.

How can shareholders obtain a hard copy of Ambrx's annual report?

Shareholders can request a free hard copy of the annual report via email.

What is Ambrx's focus in the biopharmaceutical market?

Ambrx focuses on developing Engineered Precision Biologics, including antibody drug conjugates and targeted immuno-oncology therapies.